NED Medical, Inc. — SEC Form D Filing

NED Medical, Inc. filed an SEC Form D on February 19, 2026, reporting $8.00M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
February 19, 2026
Amount reported
$8.00M
Round stage
Seed
Industry
Health Care
Website
https://nedmedical.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Liver cancer has a low survival rate and current treatments like radioembolization provide limited outcomes for patients.

Solution

NED Medical offers CombiSphere, a proprietary radioembolization therapy designed to enhance treatment options and improve patient outcomes.

Why now

With rising liver cancer diagnoses and stagnant survival rates, innovative treatment options are urgently needed.

Verdict

Investors backed NED Medical at this moment due to an urgent need for improved liver cancer treatments, betting implicitly on the potential success of CombiSphere amid stagnant survival rates. This cleared because there was a clear market need supported by innovation, not because competitors weren't already established. However, the durability of this bet is limited by high regulatory risks and the uncertain adoption of new therapies in traditional hospital settings.

Source: SEC EDGAR Form D filing